The Irish experience of kidney transplantation among recipients with prior non‐renal solid organ transplants: A retrospective study on short‐ and long‐term outcomes

2020 ◽  
Author(s):  
Atakelet A. Ferede ◽  
Clare O'Connell ◽  
Niall F. Davis ◽  
Ponnusamy Mohan ◽  
Ian Robertson ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Retrospective Study ◽  
Solid Organ ◽  
Organ Transplants ◽  
Long Term Outcomes ◽  
Short And Long Term

Short- and Long-Term Outcomes of Living Donors in Tunisia: A Retrospective Study

2010 ◽  
Vol 42 (10) ◽  
pp. 4311-4313 ◽  
Author(s):  
M. Cherif ◽  
M. Ounissi ◽  
C. Karoui ◽  
K. Boubaker ◽  
I. Helal ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Living Donors ◽  
Long Term Outcomes ◽  
Short And Long Term

MOLECULAR MARKERS OF SHORT AND LONG TERM OUTCOMES POST KIDNEY TRANSPLANTATION

2010 ◽  
Vol 90 ◽  
pp. 147
Author(s):  
D. Maluf ◽  
M. J. Scian ◽  
K. J. Archer ◽  
L. J. Suh ◽  
R. Fassnacht ◽  
...  
Keyword(s):  
Molecular Markers ◽  
Kidney Transplantation ◽  
Long Term Outcomes ◽  
Short And Long Term

scholarly journals Short and Long Term Outcomes of Combined Heart and Kidney Transplantation: A Single-Center Experience

2017 ◽  
Vol 23 (8) ◽  
pp. S130
Author(s):  
Matthew Seigerman ◽  
Maria Molina ◽  
Thomas Hanff ◽  
Jeremy Mazurek ◽  
Allison Padegimas ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Single Center ◽  
Long Term Outcomes ◽  
Single Center Experience ◽  
Short And Long Term

scholarly journals 2667. Does Ceftazidime–Avibactam (CAZ-AVI) Improve Short- and Long-Term Outcomes Among Solid-Organ Transplant (SOT) Recipients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections?

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S934-S935
Author(s):  
Jonathan Sun ◽  
Cornelius J Clancy ◽  
Ryan K Shields ◽  
Minh-Hong Nguyen
Keyword(s):  
Organ Transplant ◽  
Recurrent Infection ◽  
Solid Organ ◽  
Recurrent Infections ◽  
Long Term Outcomes ◽  
Salvage Regimen ◽  
Short Term Mortality ◽  
Short And Long Term ◽  
The Impact

Abstract Background SOT recipients are an ideal population in which to study the impact of new antibiotics, since they are particularly dependent upon drug activity to clear infections. In 3/15, FDA approved CAZ-AVI, the first new anti-CRE agent to arrive in the clinic. Our objective was to determine whether CAZ-AVI improves short- and long-term outcomes of CRE-infected SOT recipients. Methods We performed a retrospective study of SOT recipients infected with CRE since 2012, who were treated with CAZ-AVI or salvage agents for ≥ 3 days. Results 35 CRE-infected SOT recipients (14 liver, 11 lung, 6 kidney, 3 intestine, 1 heart) with bacteremia (20), pneumonia (11), intra-abdominal abscess (3) and soft-tissue infection/osteomyelitis (1) were enrolled. 16 and 19 patients (pts) were treated with CAZ-AVI and salvage agents, respectively. Types of infection or SOT, APACHE II and McCabe scores did not differ significantly between patients treated with CAZ-AVI or salvage agents. 30- and 90-d mortality rates were significantly lower among SOT recipients treated with CAZ-AVI (0% and 6%, respectively) compared with salvage agents (26% and 37%; P = 0.049 and 0.047). Among patients who survived 90 days, recurrent CRE infections were diagnosed in 53% and 17% of those treated with CAZ-AVI and a salvage regimen, respectively (P = 0.10). Median time from end of therapy for the 1st CRE infection to recurrent infection was 116 days (max 1,242) and 361 days (max 799) for CAZ-AVI and salvage regimens, respectively. Survival and recurrence-free survival were greater for treatment with CAZ-AVI and salvage agents, respectively, as measured by Kaplan–Meier (Figures). CAZ-AVI resistance developed in 37% (n = 3) of patients with recurrent infections. Recurrent isolates were genetically indistinguishable from parent isolates by core genome SNP phylogeny (< 15 SNP). Conclusion CAZ-AVI significantly reduced short-term mortality among SOT recipients with CRE infections compared with salvage regimens, but was limited by recurrent infections and emergence of resistance. The same strains caused recurrent and initial infections, suggesting that CAZ-AVI did not eliminate CRE from GI sites that serve as sources of recurrence. Optimizing outcomes in SOT recipients with CRE infections will require new agents like CAZ-AVI, and strategies to eliminate long-term colonization. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document